Search Results

GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association’s Fall Conference from a Phase II trial in Alzheimer’s disease of lead candidate GV1001

GemVax & KAEL Co., Ltd. has announced that a paper on GV1001, a novel Alzheimer’s treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal ‘Alzheimer’s Research & Therapy’.

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.

A year ago, AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to retain its relationship with the biotech’s China operations.

Adeno-associated Virus Gene Therapy Market Outlook 2025-2035:

GemVax & KAEL a clinical stage company developing novel immunotherapies based on telomerase modification announced the decision to apply for an expanded access IND for its lead candidate GV1001 to include additional investigational groups in Alzheimer’s, a disease the WHO estimates to affect 24 million people worldwide, in its clinical development program.

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.